# Day One Biopharmaceuticals

Source: https://onco.cc/companies/day-one-biopharmaceuticals/  
OnCo record `day-one-biopharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paediatric-first oncology company whose tovorafenib became the first targeted therapy approved for childhood low-grade glioma driven by BRAF fusions, following dabrafenib with trametinib (2023) for BRAF V600E tumours.

## Summary

Day One Biopharmaceuticals, based in Brisbane, California, and listed as DAWN, is a paediatric-first oncology company whose tovorafenib became the first targeted therapy approved for childhood low-grade glioma driven by BRAF fusions, following dabrafenib with trametinib (2023) for BRAF V600E tumours. Ojemda, its brand of tovorafenib, was approved in the United States in 2024 on the FIREFLY-1 trial, Ipsen holds the rights outside the United States, the LOGGIPY-2 phase 3 tests it in the first-line setting, and pimasertib, a MEK inhibitor, is being developed in combinations. OnCo links it to glioma and paediatric low-grade glioma and to the bottleneck of rare and paediatric cancers without markets, which its model of developing drugs for children first is meant to answer. Whether a company can sustain itself on paediatric indications alone is the open question. Tovorafenib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-06
- HQ: Brisbane, CA
- Type: biotech
- Website: https://www.dayonebio.com
- Ticker: DAWN

## Sources

- Official website: https://www.dayonebio.com

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Paediatric low-grade glioma](https://onco.cc/cancers/paediatric-low-grade-glioma/)
- drugs: [Tovorafenib](https://onco.cc/drugs/tovorafenib/)
- trials: [A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors](https://onco.cc/trials/nct05377996/), [DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)](https://onco.cc/trials/nct05566795/), [FIREFLY-1](https://onco.cc/trials/firefly-1/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)
- roadmaps: [Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first](https://onco.cc/roadmaps/paediatric-oncology-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/day-one-biopharmaceuticals.json